Completed PHASE1 INTERVENTIONAL 4-arm NCT02737059

Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects

A Phase I Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects

Sponsor: AstraZeneca

Conditions Constipation Drug Induced

Interventions Codeine Naloxegol codeine placebo naloxegol placebo

Updated 8 times since 2017 Last updated: Aug 28, 2017 Started: Jul 1, 2016 Primary completion: May 10, 2017 Completion: May 10, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Constipation Drug Induced and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Sep 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Aug 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2017 — Aug 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Michael Camilleri

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States